MEDICINE MAN TECHNOLOGIES, INC. AS ISSUER AND EACH OF THE GUARANTORS PARTY HERETO 13% SENIOR SECURED CONVERTIBLE NOTES DUE DECEMBER 7, 2026 INDENTURE DATED AS OF DECEMBER 7, 2021 ANKURA TRUST COMPANY, LLC AS TRUSTEE AND CHICAGO ATLANTIC ADMIN, LLC AS...Indenture • December 9th, 2021 • Medicine Man Technologies, Inc. • Services-management consulting services • New York
Contract Type FiledDecember 9th, 2021 Company Industry Jurisdiction
PROTALIX BIOTHERAPEUTICS, INC. AS ISSUER AND EACH OF THE GUARANTORS PARTY HERETO 7.50% SENIOR SECURED CONVERTIBLE NOTES DUE 2024 INDENTURE DATED AS OF AUGUST 24, 2021 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. AS TRUSTEE WILMINGTON SAVINGS FUND...Indenture • August 26th, 2021 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledAugust 26th, 2021 Company Industry JurisdictionINDENTURE, dated as of August 24, 2021, among Protalix Biotherapeutics, Inc., a Delaware corporation (“Company”), the Guarantors (as defined below) party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”), registrar, paying agent and conversion agent, and Wilmington Savings Fund Society, FSB (“WSFS”), as the collateral agent (the “Collateral Agent”).
PROTALIX BIOTHERAPEUTICS, INC. AS ISSUER AND EACH OF THE GUARANTORS PARTY HERETO 7.50% SENIOR SECURED CONVERTIBLE NOTES DUE 2021 INDENTURE DATED AS OF DECEMBER 7, 2016 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. AS TRUSTEE WILMINGTON SAVINGS FUND...Indenture • December 7th, 2016 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledDecember 7th, 2016 Company Industry JurisdictionINDENTURE, dated as of December 7, 2016, among Protalix Biotherapeutics, Inc., a Delaware corporation (“Company”), the Guarantors (as defined below) party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”), registrar, paying agent and conversion agent, and Wilmington Savings Fund Society, FSB (“WSFS”), as the collateral agent (the “Collateral Agent”).